Form 4: Ginkgo Bioworks Executive Steven P. Coen Reports Stock Transactions

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., reports acquisition and disposal of Class A Common Stock and Restricted Stock Units.

Summary

• On August 1, 2024, Steven P. Coen acquired 23,496 and 6,250 shares of Class A Common Stock through the vesting of Restricted Stock Units (RSUs).
• Following these transactions, Coen directly owns 218,554 and 224,804 shares of Class A Common Stock.
• On August 2, 2024, Coen disposed of 17,486 shares of Class A Common Stock at a price of $0.287 per share.
• After the sale, Coen directly owns 207,318 shares of Class A Common Stock.
• Coen also holds 775,377 and 268,751 Restricted Stock Units.
• The sale of shares was to cover tax withholding obligations related to the vesting of restricted stock and/or restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transactions are routine and related to compensation. The sale is to cover tax obligations, which is a common practice.

Positives

• The vesting of RSUs indicates that performance milestones were likely met, triggering the release of these equity awards.

Negatives

• The sale of shares, even if for tax purposes, could be perceived negatively by some investors as it reduces the executive's direct stake in the company.

Risks

• Sales to cover tax obligations could continue if the stock price increases and more RSUs vest.
• Significant stock sales by insiders could create downward pressure on the stock price.

Future Outlook

The document does not contain specific forward-looking statements, but future Form 4 filings will likely reflect ongoing RSU vesting and potential sales to cover tax obligations.

Industry Context

Insider transactions are common and closely monitored in the biotech industry. Investors often use this information to gauge management's confidence in the company's future prospects.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in financial analysis, with firms like Vickers Stock Research and Thomson Reuters providing data and analysis on insider trading activity.
• Comparing the volume and frequency of insider sales at Ginkgo Bioworks to those of comparable companies like Amyris or Zymergen (now acquired by Ginkgo) can provide insights into market sentiment.

Stakeholder Impact

• Shareholders may be concerned about insider selling, even if for tax purposes.
• Employees holding RSUs will be interested in the vesting schedules and tax implications.

Next Steps

• Monitor future Form 4 filings for further insider transactions.
• Assess the overall trend of insider buying and selling activity to gauge management's sentiment.

Key Dates